Featured Research

from universities, journals, and other organizations

New Prognostic Markers For Gastric Cancer Patients

Date:
May 20, 2008
Source:
World Journal of Gastroenterology
Summary:
In a recent study to understand the coordinated regulation of cell-cell and cell-matrix interactions during malignant transformation, the researchers studied the coexpression of E-cadherin£¬syndecan-1 and integrin beta3 by immunohistochemical study in gastric carcinomas. The results from the study confirm the correlation between expressions of cell adhesion molecules (CAMs) and gastric cancer. They suggest the coexpression of these can be used to identify the prognosis of gastric carcinoma.

In a recent study to understand the coordinated regulation of cell-cell and cell-matrix interactions during malignant transformation, the researchers studied the coexpression of E-cadherin£¬syndecan-1 and integrin beta3 by immunohistochemical study in gastric carcinomas. The results from the study confirm the correlation between expressions of cell adhesion molecules (CAMs) and gastric cancer. They suggest the coexpression of these can be used to identify the prognosis of gastric carcinoma.

In standard clinical settings, DNA microarrays are currently unsuitable for routine use. Prognostic classification on formalin-fixed paraffin-embedded tissues is required. In this study, we looked for new molecular markers for identifying the prognosis of gastric cancer patients.

This study was performed by a team led by Professor Zhong-Sheng Zhao.

The team identified that syndecan-1, E-cadherin and integrins highly correlated with each other as intracellular adhesion molecular complexes. We suggest the results of co-examination of them can be important indexes for the prognosis of gastric carcinoma. In the view of the authors, to date no clear mechanism has been found to explain the interaction of the three molecules, and no clinical research has been done to verify the findings.

Traditional clinicopathologic factors and several interesting molecules, including cell cycle regulation factors such as p27 or cyclin E, cell adhesion molecules such as E-cadherin, angiogenic factors such as vascular endothelial growth factor and placenta growth factor, oncogenes such as c-erbB2 and c-myc, and tumor suppressor genes such as p53, have been reported to correlate to the prognosis of gastric cancer patients. Cell adhesion is one of important steps in the multi-step process of gastric cancer pathogenesis.

Further research should collect more samples and emphasize the importance of studying multiple genetic alterations in concert.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Chu YQ, Ye ZY, Tao HQ, Wang YY, Zhao ZS. Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World J Gastroenterol 2008; 14(13): 1990-1996 [link]

Cite This Page:

World Journal of Gastroenterology. "New Prognostic Markers For Gastric Cancer Patients." ScienceDaily. ScienceDaily, 20 May 2008. <www.sciencedaily.com/releases/2008/05/080520122738.htm>.
World Journal of Gastroenterology. (2008, May 20). New Prognostic Markers For Gastric Cancer Patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/05/080520122738.htm
World Journal of Gastroenterology. "New Prognostic Markers For Gastric Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2008/05/080520122738.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins